NCT06773130

HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma

An Exploratory Clinical Study of HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: West China Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of HRS-4642 combined with Nimotuzumab in patients with recurrent or metastatic pancreatic ductal adenocarcinoma.

Detailed description

This study is an open, single center, exploratory clinical trial aimed at evaluating the efficacy and safety of HRS-4642 combined with Nimotuzumab in the treatment of patients with recurrent or metastatic pancreatic ductal adenocarcinoma.

Conditions

• Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

Type	Name	Description
DRUG	HRS-4642	HRS-4642 will be administrated per dose level in which the patients are assigned.
DRUG	Nimotuzumab	400mg，ivgtt，d1，qw

Timeline

• Start date: 2025-02-10
• Primary completion: 2027-01-01
• Completion: 2027-03-01
• First posted: 2025-01-14
• Last updated: 2025-11-17

Locations

1 site across 1 country: China